| scholarly article | Q13442814 |
| P2093 | author name string | Gay NJ | |
| De Serres G | |||
| Law B | |||
| Edmunds WJ | |||
| Brisson M | |||
| P433 | issue | 3 | |
| P921 | main subject | epidemiology | Q133805 |
| immunization | Q1415366 | ||
| P304 | page(s) | 651-669 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Epidemiology and Infection | Q5382708 |
| P1476 | title | Modelling the impact of immunization on the epidemiology of varicella zoster virus | |
| P478 | volume | 125 |
| Q28271873 | A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia |
| Q34339039 | Adolescent and adult pertussis vaccination: computer simulations of five new strategies |
| Q39431987 | Chickenpox vaccination, not chickenpox, should be routine for Canadian children. |
| Q36470500 | Chickenpox, chickenpox vaccination, and shingles |
| Q37521887 | Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? |
| Q35887150 | Clinical benefits of routine varicella vaccination for adults |
| Q35627422 | Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? |
| Q34687613 | Computational immunology: The coming of age. |
| Q33804835 | Computational modeling of interventions and protective thresholds to prevent disease transmission in deploying populations |
| Q60220652 | Contacts with children and young people and adult risk of suffering herpes zoster |
| Q28468596 | Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia |
| Q81661613 | Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology |
| Q51871886 | Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. |
| Q92593496 | Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model |
| Q50887964 | Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. |
| Q37229923 | Cost-effectiveness of varicella vaccination programs: an update of the literature |
| Q36171295 | Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy |
| Q37135445 | Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination |
| Q80681662 | Deterministic SIR (Susceptible-Infected-Removed) models applied to varicella outbreaks |
| Q44957973 | Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics |
| Q81690452 | Disparities in varicella vaccine coverage in the absence of public funding |
| Q36252698 | Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster |
| Q54646751 | Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations. |
| Q33551026 | Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease |
| Q39550770 | Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. |
| Q39549252 | Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5. |
| Q81819646 | Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases |
| Q79965616 | Economic evaluation of varicella vaccination in Spain: results from a dynamic model |
| Q35026965 | Economic evaluations of varicella vaccination programmes: a review of the literature |
| Q35571925 | Epidemiological game-theory dynamics of chickenpox vaccination in the USA and Israel |
| Q35607755 | Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. |
| Q33574978 | Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). |
| Q50984534 | Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. |
| Q43912397 | Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. |
| Q55338707 | Evaluation of the effect of chickenpox vaccination on shingles epidemiology using agent-based modeling. |
| Q28111950 | Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox |
| Q59351071 | Global impact of varicella vaccination programs |
| Q34785366 | Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review |
| Q46366563 | Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? |
| Q57482005 | Herpes zoster in the context of varicella vaccination - An equation with several variables |
| Q39704094 | Herpes zoster infection, vaccination and immunocompromised rheumatology patients |
| Q33956779 | Herpes zoster vaccine for the elderly: boosting immunity |
| Q35886434 | Hospitalization with varicella and shingles before and after introduction of childhood varicella vaccination in Germany |
| Q56879722 | How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia |
| Q37660930 | Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making? |
| Q44388059 | Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs |
| Q33591264 | Impact of varicella vaccine on varicella-zoster virus dynamics |
| Q52668918 | Incidence and mortality rates of varicella among end stage renal disease (ESRD) patients in Singapore General Hospital, a 12-year review. |
| Q42634700 | Infections with varying contact rates: application to varicella. |
| Q47556386 | Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study |
| Q37643309 | Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians |
| Q40640266 | Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster |
| Q56880767 | Intradermal zoster vaccines: good for the old and the young? |
| Q47649725 | Mathematical models and vaccination strategies |
| Q51647306 | Methodology of the sensitivity analysis used for modeling an infectious disease. |
| Q26738745 | Microbiology laboratory and the management of mother-child varicella-zoster virus infection |
| Q40686391 | Modeling and predicting the long-term effects of various strategies and objectives of varicella-zoster vaccination campaigns |
| Q83117567 | Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster |
| Q51790294 | Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. |
| Q45421406 | Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia |
| Q46174982 | Modelling the impact of varicella vaccination on varicella and zoster. |
| Q33703682 | Modelling the transmission and control strategies of varicella among school children in Shenzhen, China |
| Q37932527 | Molecular studies of the Oka varicella vaccine |
| Q33683179 | Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox |
| Q27312388 | Negative attitude and low intention to vaccinate universally against varicella among public health professionals and parents in the Netherlands: two internet surveys |
| Q34429296 | Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay |
| Q39689778 | Periodicity of varicella-zoster virus in the presence of immune boosting and clinical reinfection with varicella |
| Q51439781 | Perspectives on optimal control of varicella and herpes zoster by mass routine varicella vaccination. |
| Q34683751 | Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries |
| Q47242634 | Post-herpetic neuralgia - a review of current management and future directions |
| Q37461377 | Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response |
| Q36642986 | Prevention of shingles: safety and efficacy of live zoster vaccine |
| Q45326018 | Projections of zoster incidence in Australia based on demographic and transmission models of varicella-zoster virus infection. |
| Q93093594 | Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults |
| Q28315869 | Recommendations for the Management of Herpes Zoster |
| Q37405340 | Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention |
| Q91311587 | Seeking the optimal schedule for chickenpox vaccination in Canada: Using an agent-based model to explore the impact of dose timing, coverage and waning of immunity on disease outcomes |
| Q27006862 | Serial intervals of respiratory infectious diseases: a systematic review and analysis |
| Q35666726 | Sero-Prevalence of Antibodies against Varicella Zoster Virus in Children under Seven-Years Old in 2012 in Tehran, Iran |
| Q34313029 | Seroprevalence of varicella-zoster virus and predictors for seronegativity in the Amsterdam adult population |
| Q51226815 | Shingles in Alberta: before and after publicly funded varicella vaccination. |
| Q36121450 | Should the UK introduce varicella vaccine? |
| Q42182922 | Should varicella vaccine be included in the routine immunization programme? |
| Q40270154 | Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15. |
| Q34416710 | Successes and challenges in varicella vaccine |
| Q38781301 | The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling |
| Q46988238 | The case against universal varicella vaccination |
| Q51412536 | The changing epidemiology of varicella and herpes zoster in Hong Kong before universal varicella vaccination in 2014. |
| Q39694343 | The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study. |
| Q45399810 | The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. |
| Q43681569 | The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom |
| Q77526064 | The cost-effectiveness of varicella vaccination in Canada |
| Q43427510 | The epidemiology of chickenpox in UK 5-year olds: an analysis to inform vaccine policy. |
| Q61798456 | The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting |
| Q35886772 | The impact of ten years of infant universal Varicella vaccination in Sicily, Italy (2003-2012) |
| Q33703581 | The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster |
| Q37120852 | Too little of a good thing: a paradox of moderate infection control |
| Q33273781 | Using GIS to create synthetic disease outbreaks |
| Q51997400 | Using computer simulations to compare pertussis vaccination strategies in Australia. |
| Q37672263 | Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England |
| Q40278402 | Varicella |
| Q34101345 | Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study |
| Q47607699 | Varicella and herpes zoster vaccine development: lessons learned |
| Q39394364 | Varicella vaccination - the global experience |
| Q35035512 | Varicella vaccination alters the chronological trends of herpes zoster and varicella |
| Q60713444 | Varicella vaccination coverage in Bavaria (Germany) after general vaccine recommendation in 2004 |
| Q36362821 | Varicella vaccination in Australia. |
| Q34263829 | Varicella vaccination in England and Wales: cost-utility analysis |
| Q46496322 | Varicella vaccination in Germany. A provisional appraisal in the context of MMR vaccination |
| Q35871122 | Varicella vaccination in Italy : an economic evaluation of different scenarios |
| Q79451173 | Varicella vaccine: local convenience or global equity? |
| Q93189986 | Varicella zoster virus vaccines: an update |
| Q41630514 | Varicella-zoster virus vaccination under the exogenous boosting hypothesis: two ethical perspectives |
| Q42273664 | Zostavax : a subcutaneous vaccine for the prevention of herpes zoster |
| Q79869889 | [Contribution of modelization to our knowledge of the spread of infectious diseases and their prevention] |
| Q80482622 | [Cost-effectiveness of varicella vaccination in Spanish adolescents] |
Search more.